Orlistat (Tetrahydrolipstatin) is intended for the body weight control.
Orlistat provides a reduction of body weight, maintaining it at the appropriate level and preventing the re-addition of body weight.
By reducing body weight with Orlistat, it is possible to improve carbohydrate metabolism in patients with type 2 diabetes, which may reduce the dose of hypoglycemic drugs.
The therapeutic action of Orlistat occurs without absorption into the systemic blood circulation.
Orlistat is a specific inhibitor of long-acting gastrointestinal lipases.
The inactivated enzyme is not able to cleave the food fats coming in the form of triglycerides, to absorbable free fatty acids and monoglycerides. Undigested triglycerides are not absorbed, and therefore decreases the flow of calories in the body, which leads to a decrease of body weight.
Orlistat increases the concentration of fat in the feces after 24-48 hours after receiving the medication.
In clinical studies in patients taking Orlistat, there was a large loss of body weight compared with patients on diet therapy. The decrease of body weight in patients taking Orlistat began already during the first 2 weeks after the start of treatment.
- treatment of patients with obesity (body mass index> 30 kg / m2) or patients with overweight (body mass index> 28 kg / m2) with risk factors associated with obesity, in combination with a moderately low-calorie diet.
- patients with type 2 diabetes with overweight or obesity, in combination with hypoglycemic drugs (metformin, sulfonylurea derivatives and / or insulin) and / or a moderately low-calorie diet
Package: 84 capsules 120 mg